Citigroup’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $31.4M | Sell |
185,658
-18,446
| -9% | -$3.19M | 0.01% | 850 |
|
|
2025
Q4 | $37.3M | Buy |
204,104
+62,091
| +44% | +$8.67M | 0.02% | 765 |
|
|
2025
Q3 | $17.2M | Buy |
142,013
+57,002
| +67% | +$6.42M | 0.01% | 1162 |
|
|
2025
Q2 | $8.87M | Buy |
85,011
+45,842
| +117% | +$4.85M | ﹤0.01% | 1452 |
|
|
2025
Q1 | $4.57M | Sell |
39,169
-3,792
| -9% | -$432K | ﹤0.01% | 1983 |
|
|
2024
Q4 | $3.63M | Buy |
42,961
+7,342
| +21% | +$675K | ﹤0.01% | 2276 |
|
|
2024
Q3 | $3.2M | Buy |
35,619
+18,821
| +112% | +$1.64M | ﹤0.01% | 2246 |
|
|
2024
Q2 | $1.35M | Sell |
16,798
-78,274
| -82% | -$5.8M | ﹤0.01% | 2665 |
|
|
2024
Q1 | $7.59M | Sell |
95,072
-6,655
| -7% | -$559K | 0.01% | 1439 |
|
|
2023
Q4 | $8.1M | Sell |
101,727
-935
| -0.9% | -$62.5K | 0.01% | 1320 |
|
|
2023
Q3 | $7.18M | Buy |
102,662
+39,904
| +64% | +$2.98M | 0.01% | 1262 |
|
|
2023
Q2 | $4.51M | Buy |
62,758
+14,436
| +30% | +$1.06M | ﹤0.01% | 1551 |
|
|
2023
Q1 | $2.98M | Buy |
48,322
+7,724
| +19% | +$507K | ﹤0.01% | 1765 |
|
|
2022
Q4 | $3.13M | Sell |
40,598
-7,807
| -16% | -$467K | ﹤0.01% | 1739 |
|
|
2022
Q3 | $2.16M | Sell |
48,405
-11,341
| -19% | -$567K | ﹤0.01% | 2088 |
|
|
2022
Q2 | $2.29M | Buy |
59,746
+50,842
| +571% | +$1.61M | ﹤0.01% | 2011 |
|
|
2022
Q1 | $370K | Sell |
8,904
-3,380
| -28% | -$105K | ﹤0.01% | 3708 |
|
|
2021
Q4 | $464K | Sell |
12,284
-34,587
| -74% | -$1.27M | ﹤0.01% | 3853 |
|
|
2021
Q3 | $1.54M | Buy |
46,871
+39,289
| +518% | +$1.53M | ﹤0.01% | 2744 |
|
|
2021
Q2 | $512K | Buy |
7,582
+1,608
| +27% | +$96.5K | ﹤0.01% | 3691 |
|
|
2021
Q1 | $338K | Sell |
5,974
-7,297
| -55% | -$513K | ﹤0.01% | 3725 |
|
|
2020
Q4 | $1.08M | Buy |
13,271
+2,024
| +18% | +$151K | ﹤0.01% | 3468 |
|
|
2020
Q3 | $801K | Sell |
11,247
-192,320
| -94% | -$15M | ﹤0.01% | 3469 |
|
|
2020
Q2 | $16.8M | Buy |
203,567
+191,673
| +1,612% | +$14.8M | 0.01% | 930 |
|
|
2020
Q1 | $700K | Buy |
11,894
+3,547
| +42% | +$289K | ﹤0.01% | 3542 |
|
|
2019
Q4 | $862K | Buy |
8,347
+5,838
| +233% | +$236K | ﹤0.01% | 3914 |
|
|
2019
Q3 | $51K | Buy |
2,509
+2,487
| +11,305% | +$63.9K | ﹤0.01% | 6111 |
|
|
2019
Q2 | $1K | Sell |
22
-18,590
| -100% | -$373K | ﹤0.01% | 7657 |
|
|
2019
Q1 | $265K | Buy |
+18,612
| New | +$173K | ﹤0.01% | 4825 |
|
|
2017
Q3 | – | Sell |
-1
| Closed | – | – | 7246 |
|
|
2017
Q2 | $0 | Sell |
1
-38
| -97% | -$159 | ﹤0.01% | 7338 |
|
|
2017
Q1 | $0 | Sell |
39
-3,406
| -99% | -$16.3K | ﹤0.01% | 7177 |
|
|
2016
Q4 | $23K | Buy |
3,445
+2,533
| +278% | +$17.8K | ﹤0.01% | 6472 |
|
|
2016
Q3 | $7K | Sell |
912
-209
| -19% | -$1.58K | ﹤0.01% | 6651 |
|
|
2016
Q2 | $8K | Buy |
+1,121
| New | +$10.3K | ﹤0.01% | 6622 |
|
Other funds holding AXSM
VPM
VCM
DTC
Citigroup's AXSM Position: Q1 2026 in Review
Citigroup reduced its Axsome Therapeutics (AXSM) stake by 9% in Q1 2026, selling an estimated $3.19M and leaving 185,658 shares worth $31.4M. The position accounts for 0.01% of the portfolio, ranked #850.
Citigroup first reported a position in AXSM in Q2 2016 and has held it in 34 quarters since. The position peaked at $37.3M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.
- Citigroup held 185,658 shares of Axsome Therapeutics worth $31.4M as of Q1 2026.
- Citigroup sold 18,446 Axsome Therapeutics shares in Q1 2026, an estimated $3.19M.
- Axsome Therapeutics made up 0.01% of Citigroup's portfolio in Q1 2026, its #850 holding.
- Citigroup first reported a position in Axsome Therapeutics in Q2 2016 and has held it in 34 quarters since.
- Citigroup's Axsome Therapeutics position peaked at $37.3M in Q4 2025.
- 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.